Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 5FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Classical hematology 1

Conditions

Prostatic Neoplasms 53Neoplasms 8Urinary Bladder Neoplasms 4Neoplasm Metastasis 4Urinary Incontinence 3Erectile Dysfunction 3Pulmonary Disease, Chronic Obstructive 2Non-Muscle Invasive Bladder Neoplasms 2Lung Neoplasms 2Kidney Failure, Chronic 2Heart Failure 2Dementia 2Breast Neoplasms 2Weight Loss 1Urogenital Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate cancer, familial 1Prostate Cancer Prevention 1Prostate Cancer Diagnosis 1Patients With Prostate Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Obesity 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Motor Activity 1Male Urogenital Diseases 1

Interventions

olaparib 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Hereditary Sensory and Autonomic Neuropathies × Genitourinary × Clear all
NCT04038502 2025-08-20

COBRA

VA Office of Research and Development

Phase 2 Recruiting
100 enrolled
Classical hematologyGenitourinary

Fanconi Anemia, Complementation Group N, Fanconi Anemia, Complementation Group D1, Hereditary Sensory and Autonomic Neuropathies, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡